GNFTF - Cirius Therapeutics IPO: At Phase 2 And Results Should Arrive In 2019
Many institutional investors will assess Cirius Therapeutics (CSTX) as the company's leading product candidate is at Phase 2 of development and results will be released in the second half of 2019. In addition, it is beneficial that the company has no debt and expects to convert all its convertible securities as the IPO goes live. With that, it is also quite beneficial that many institutional investors decided to acquire shares before the IPO. They all seemed to trust the data obtained so far.
Source: Prospectus
Source: Prospectus
Business
Founded in 2015, Cirius is a clinical-stage